Navigating the Hormonal Journey: A Clinician's Guide to Perimenopause, Menopause, and Global Variation in Care
Amina Shaukat MD, MQM, CPHQ 1*, Hassan Shaukat MD, MSc 2, Mohammad Asjed 3,
Nadia Shaukat MD, PhD, FRCPCH 4
*Correspondence to: Amina Shaukat, MD, MQM, CPHQ, Mental Health Division, Northern Health, 185 Cooper Street, Epping; Victoria, 3076, Melbourne, Australia.
Copyright
© 2026 Amina Shaukat, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 28 September 2026
Published: 01 October 2026
DOI: https://doi.org/10.5281/zenodo.23079449
Abstract
Menopause isn't a single event — it's a years-long hormonal unwinding, unstable long before it settles. As the follicle pool shrinks, inhibin B drops first, freeing FSH to climb; progesterone gives way years before estrogen does, and AMH declines more steadily. STRAW+10 remains the framework clinicians lean on to stage where a woman sits, using cycle-length changes and time since her last period rather than a blood draw. Early post menopause under this framework actually runs five to eight years, not the one or two often assumed. Once estrogen settles low, effects show up everywhere at once, not one system at a time. Severe hot flashes track with higher cardiovascular and bone risk down the line — an association worth stressing, not a proven cause — mood and brain fog seem tied more to how sharply hormones swing than how low they go; lipids, bone density, and midsection weight gain move together; and vaginal and urinary symptoms, unlike hot flashes, don't fade with time if left alone. Individualized, timing-aware hormone therapy is still the most effective tool available for symptoms — it treats hot flashes and protects bone, not the heart — transdermal estradiol especially for cardiometabolic risk, with SSRIs, SNRIs, and newer neurokinin antagonists (fezolinetant and now, elinzanetant) as real options for women who can't use hormones. This review also looks at how unevenly this care is delivered worldwide: primary care hands out prescriptions readily in the UK and Australia, while women in the Gulf often see several specialists before hormone therapy comes up. How much of that gap comes from the health system itself, rather than biology, is a question this review keeps returning to.
Keywords: Perimenopause, Menopause, Menopausal hormone therapy (MHT), Vasomotor symptoms, STRAW+10 staging, Genitourinary syndrome of menopause, Global health disparities, Estrogen.
The Hormonal Trajectory Is Not Linear
The mental image most people have of menopause is a dimmer switch slowly turning estrogen down. It is closer to a light that fluctuates unpredictably before finally declining. As the follicle pool shrinks, inhibin B drops first, which frees the pituitary to push FSH higher [1,3].
That extra FSH can actually squeeze more estradiol out of the remaining follicles, so a woman in early perimenopause may briefly run hotter on estrogen than she did in her twenties, before the supply runs out for good [1]. This is exactly why a single blood test rarely tells you anything reliable in this phase: catch her on a peak day and she looks fine; catch her on a trough and she looks menopausal. Progesterone, not estrogen, is usually the first hormone to give way in a lasting sense, often years ahead of any estrogen change, as ovulation becomes patchy [1]. That is a likely contributor to the heavier bleeding and disrupted sleep women report long before a single hot flash arrives [6].
One caveat, though: don't let progesterone withdrawal become the automatic explanation for heavy or irregular bleeding. Past 45, or with risk factors like obesity, diabetes, tamoxifen use, or a family history of endometrial or colorectal cancer, that bleeding needs a look for structural causes and endometrial hyperplasia or malignancy first — an ultrasound, sometimes a sample of the lining — before it gets filed under 'just perimenopause' [26].
AMH declines in a much more orderly, dose-dependent fashion and is a decent proxy for where someone sits on the reserve curve, even if it is not used alone to stage menopause [1]. Testosterone, meanwhile, has usually already halved by the time perimenopause starts and barely moves after that [1]. Once the final period has passed, the fluctuation stops: estradiol settles at a low, stable floor over the following year or two, and FSH stays persistently high because the feedback loop that used to rein it in is simply gone [3].
Staging it properly: why STRAW+10 still matters
Clinicians reach for the STRAW+10 (Stages of Reproductive Aging Workshop) framework because it gives structure to what otherwise feels like a moving target [22]. It divides the transition into early and late reproductive stages, early and late perimenopause, and early and late postmenopause, using cycle-length variability and time since the final menstrual period as anchors rather than relying on a single hormone cut-off [22]. Early perimenopause is marked by cycle-length variability of seven days or more from a woman's usual pattern; late perimenopause by at least sixty days of amenorrhea [22]. Postmenopause isn't one flat stage either. Early postmenopause (+1) runs five to eight years, not one or two, and breaks into three substages: the first year after the final period, when FSH and estradiol are still moving fast (+1a); a second year of slower change (+1b); then three to six more years while both settle at a new baseline (+1c) [22]. Late postmenopause (+2) only starts once that settling is done, and from there it's ageing — genitourinary atrophy, bone loss — doing most of the work, not the hormones themselves [22]. This staging matters practically because it tells a clinician roughly how far along a patient is without needing serial hormone draws, and because symptom burden and cardiometabolic risk both track more closely with stage than with age alone. It is not a perfect system — women with irregular cycles from other causes, or those on hormonal contraception, do not map onto it cleanly — but it remains the most widely used common language between researchers and clinicians internationally.
Hot flashes aren't just uncomfortable — they may be clinically informative
Most women get them, some barely notice, and a minority are still having them a decade after their last period [7]. What is easy to overlook clinically is that severe vasomotor symptoms are associated with higher long-term cardiovascular risk, lower bone density, and more cognitive complaints [7,19] — though this is an association, not proof that the hot flashes themselves are doing the damage; they may just be a visible marker of the same underlying vascular process, worth treating as a signal, not just a nuisance. The mechanism is thought to centre on the KNDy neuron population in the hypothalamus, where falling estrogen disinhibits neurokinin B signalling and narrows the thermoneutral zone, so the body triggers a full sweating-and-flushing response to a temperature swing that would normally go unnoticed. That mechanistic detail is not academic trivia: it is the same pathway the newer non-hormonal drugs discussed in Section 3 were built to target.
Mood, brain fog, and sleep are more tangled together than they look
Depression risk climbs two- to four-fold in perimenopause, and current evidence points less at how low estrogen goes and more at how sharply it swings day to day [4,5]. The word-finding trouble and fogginess patients describe has real imaging correlates: reduced grey and white matter volume and greater amyloid deposition have been reported in midlife women compared with age-matched men, with menopausal status among the strongest predictors of this pattern [14]. Whether early estrogen treatment protects against later dementia remains an open research question rather than a settled one [13]. Sleep is affected from several directions at once — night sweats, mood, and a likely direct effect on sleep architecture — and poor sleep then drags mood and daytime function down further [6]. In clinic, this cluster is probably the most under-treated of the lot, because a woman describing brain fog and poor sleep is often screened for depression or referred for a sleep study before anyone asks where she is in her menstrual transition.
Heart, bone, and waistline shift together, not separately
Lipids move in an unfavourable direction and vascular function changes across the transition; women with severe hot flashes appear to carry a substantially higher coronary and stroke risk than those without, in observational cohorts [19]. That doesn't turn MHT into a cardiovascular-prevention drug, though — it isn't one, and shouldn't be prescribed as one [11,23,24]; its job is symptom control and bone protection. Route and timing do most of the work in the cardiovascular conversation specifically: oral estrogen carries more stroke risk, especially at higher doses, used for years, or started past 60 or a decade out from the final period, while transdermal estradiol hasn't shown that same rise [8,11,24]. Clot risk follows the same pattern — lower with the patch or gel than the pill [8,11,24]. So the real risk conversation is about dose, route, and timing, not a blanket verdict on hormones and the heart. Bone loss is fastest in the first few years after the final period, not a slow decline, and correlates directly with estradiol and inversely with FSH/LH [12,17]. That 5–7 kg figure oversells it, though. Longitudinal data from SWAN suggest ageing does most of the heavy lifting on the scale in midlife, while menopause itself changes where the weight sits more than how much of it there is — more central, more abdominal, less lean mass [15]. It's probably more useful to tell a patient her shape is changing than to promise her a number on the scale. A woman's premenopausal estradiol level appears to predict her later diabetes risk better than how fast hormones changed during the transition itself [2]. Taken together, these three systems do not fail independently: a woman with early, severe bone loss is statistically more likely to also be carrying adverse lipid changes and central adiposity, which argues for an integrated risk conversation rather than three separate referrals to cardiology, endocrinology, and orthopaedics.
The most under-recognised symptom: genitourinary syndrome of menopause
Vaginal dryness and urinary changes — genitourinary syndrome of menopause (GSM) do not improve with time the way hot flashes eventually do; they tend to progress if untreated [16,19]. Low-dose local vaginal estrogen treats this effectively with minimal systemic absorption and is generally considered safe even when systemic MHT is contraindicated or not desired [11]. That holds for most women, but it gets more complicated with a history of hormone-sensitive breast cancer, especially on an aromatase inhibitor — even the small amount absorbed from a vaginal cream or ring has raised concern there. It's still an option once moisturisers and lubricants haven't worked, but loop the treating oncologist in first, particularly for women on an aromatase inhibitor rather than tamoxifen, since aromatase inhibitors leave so little circulating estrogen that even a small local rise counts for more [25]. It rarely comes up unless a clinician asks directly, and in our experience a simple, specific question — 'has sex become uncomfortable, or has urination changed?' — uncovers far more than waiting for a patient to volunteer it. Left untreated, GSM is also a driver of recurrent urinary tract infections in postmenopausal women, which is often treated repeatedly with antibiotics rather than addressed at its estrogen-deficient source.
Worth a separate word, given this journal's readership: women who reach menopause through cancer treatment rather than the slow transition described above. Surgery, chemotherapy, or ovarian suppression can push a woman into menopause overnight, and systemic MHT is usually off the table after hormone-receptor-positive breast cancer. The non-hormonal options in Section 3 — SSRIs/SNRIs, fezolinetant, elinzanetant, gabapentin — plus moisturisers, lubricants, and case-by-case vaginal estrogen for GSM, carry most of the load here. A menopause specialist working alongside oncology is worth bringing in when symptoms are severe or the picture isn't clear [25].
Hormone therapy: routes, doses, and the shared-decision conversation
For vasomotor symptoms specifically, nothing outperforms MHT — roughly 75% symptom reduction at standard dose, closer to 65% at low dose, and the ultra-low-dose transdermal patches often underwhelm in older patients, which is worth setting expectations around before starting one [7]. The basic rule holds: estrogen alone if the uterus is gone, estrogen plus a progestogen if it is not, because unopposed estrogen against an intact uterus invites endometrial hyperplasia [7]. MHT, even combined estrogen-progestogen formulations, is not a reliable contraceptive, and perimenopausal women who are still sexually active should be counselled separately on contraception if pregnancy is a concern. Route matters more than most patients realise: oral estrogen passes through the liver first and raises clotting factors and triglycerides, while transdermal (patch, gel, or spray) estradiol bypasses that first-pass effect and is generally the preferred route for anyone with cardiometabolic or thrombotic risk factors [8,11]. Micronized progesterone, taken at night, tends to be better tolerated than synthetic progestins and carries a mild sedative effect that some women find genuinely useful for sleep. The WHI story has kept evolving rather than settling, with more than twenty years of follow-up now in: stroke and clotting risk with MHT track age at start, time since menopause, dose, formulation, and — most reliably — route, with oral coming out worse and transdermal estradiol better [8,11,23,24]. That's pushed the guidelines toward individualised, timing- and route-aware decisions, not toward calling MHT heart-protective — it still isn't, and it's still prescribed for symptoms and bone, not the heart [23,24]. Before starting anyone, we still work through the basics: personal and family history of breast and endometrial cancer, cardiovascular disease, clotting history, bone density where relevant, and baseline metabolic and liver panels [7].
When hormones aren't the answer
Not every patient wants or can have hormones, and there are now several real alternatives. One detail matters in choosing which SSRI or SNRI: paroxetine and fluoxetine block CYP2D6, the enzyme tamoxifen needs to become its active form, so they can blunt tamoxifen's effect. Venlafaxine, desvenlafaxine, or citalopram/escitalopram sidestep that problem and are the better picks for anyone on tamoxifen [29]. Gabapentin and menopause-specific CBT also belong on this list now — both have real evidence behind them for hot flashes and the sleep disruption that comes with them, and current nonhormone-therapy guidance backs both [30]. The neurokinin antagonists are the newest addition, and a genuinely different mechanism: they work directly on the KNDy pathway in the hypothalamus described earlier, rather than trying to replace estrogen. Fezolinetant came first; elinzanetant, a dual NK1/NK3 blocker, followed, and both have cut hot-flash frequency and severity in randomised trials [10,28]. Fezolinetant does now carry a boxed warning for rare, serious liver injury, though — check liver function before starting, again a few times in the first months, skip it in anyone with existing liver disease, and tell patients what to watch for [27].
Testosterone has a legitimate, though narrower than often assumed, guideline-backed role: current international consensus supports its use specifically for appropriately diagnosed Female Sexual Interest/Arousal Disorder, or FSIAD — and only once GSM, dyspareunia, medication side effects, and relationship or psychological factors have all been worked through, not as a first response to 'my libido is low' [9]. At physiologic doses, androgenic side effects — acne, unwanted hair growth — are uncommon, under 5% in most series [9]. Beyond medication, the basics still carry real weight: calcium and vitamin D sized to diet and deficiency risk rather than the same number for everyone, resistance training to preserve muscle mass, and weight-bearing exercise for bone [12]. Phytoestrogens and other 'natural' options come up constantly in consultations, and the evidence there is genuinely mixed — worth discussing honestly rather than dismissing outright or oversimplifying as harmless [19].
Same Biology, Very Different Care: A Geographic Comparison
This is the part most reviews leave out, and it matters more than any single hormone level: two women with identical FSH and identical hot flashes, one in Manchester and one in Al Ain, are likely to receive very different care.
That 'knowledge-practice gap' deserves a closer look than one chart can give it. Tracing the studies behind those numbers, the 14% knowledge figure comes from a 2021 Dubai survey (n=591); the 48% usage figure comes from an earlier, separate study in Abu Dhabi/Sharjah (n=220) [20]. Different women, different cities, different years — not one cohort's before-and-after. What the surveys do show, taken together, is that both knowledge and use swing widely depending on who and where you ask, and that physicians themselves are part of the story: in one Saudi survey, only around 60% agreed HRT should be offered routinely to symptomatic women [21]. Cultural attitudes, a preference for herbal remedies, and inconsistent counselling all get raised as reasons in this literature, though none of them has been weighed against the others in any rigorous way [20].
The UK and Australia illustrate a different pattern: primary care physicians are the default gateway to MHT, and public menopause campaigns have pushed the conversation into mainstream media — the barrier there is less about willingness and more about consultation time. East Asian protocols, by contrast, are the most standardised of the group, building bone density, mammography, and metabolic screening into a single structured visit rather than leaving it to clinician discretion [7]. Central and Eastern European practice sits somewhere between the European specialist-endocrinology model and the more primary-care-driven Anglophone systems — MHT prescribing is guided by national gynaecological societies rather than a single unified body, which produces more regional variation within Europe itself than the table above can fully capture. None of this is really about which guideline is 'correct' — the underlying biology is essentially the same everywhere. What differs is who gets asked the right questions, and who is believed when they answer.
What We Still Don't Know
A few gaps are worth naming honestly rather than glossing over. We still cannot reliably separate how much of the mood and cognitive symptom burden comes from absolute hormone level versus the rate of change, which matters because it would change how we counsel and treat [4,5].
Pharmacogenomic dosing using markers like CYP2D6 status to individualise MHT is an active research area but nowhere near routine practice yet [9]. Women with pre-existing conditions such as type 1 diabetes are navigating menopause on very little dedicated evidence, with most guidance extrapolated from the general population [18]. And cross-country comparative data of the kind in Section 4 remains thin and unevenly collected: most of what exists on Gulf and South Asian practice comes from single-country, often single-city surveys rather than coordinated regional registries, which makes true apples-to-apples comparison harder than it should be, and the countries chosen for Section 4 were picked to illustrate contrast, not pulled from a systematic comparison of every national guideline (see the methodology note above).
Where This Leaves Us
Perimenopause and menopause are not a single hormonal event but a multi-year process — first unstable, then sustained — that touches bone, heart, brain, mood, metabolism, and pelvic health, not just the reproductive system. Biology sets the trajectory. But whether a woman gets asked the right questions, and gets timely access to individualised care, may matter just as much for how she fares — though no study has actually put the two side by side to say for certain. Individualised, timing-aware menopausal hormone therapy remains the most effective tool available for moderate-to-severe symptoms, but narrowing the geographic and health-system gap in who is offered it, and who is asked the right questions in the first place, may do as much for global menopause outcomes as any single new drug on the horizon.
References